New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 29, 2012
14:49 EDTTHRXFDA panel: Theravance's Vibativ suitable when no alternatives in HAP
Reported by Bloomberg. Theravance shares remain halted for trade as FDA panel votes on Theravance drug for expanded indication to treat Hospital-acquired pneumonia, or HAP.
News For THRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
08:15 EDTTHRXGlaxoSmithKline and Theravance announce launch of Anoro in Spain
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Anoro in Spain following the approval in Europe in May 2014. Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro Ellipta is a combination of two bronchodilators, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, in a single dry powder inhaler, the Ellipta. The approved dose of UMEC/VI is 55/22mcg. UMEC/VI has been developed under the 2002 LABA collaboration agreement between Glaxo Group Limited and Theravance.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use